Drug Trial Radar · NCT07824193
Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Jan 15, 2025
Primary completion
Apr 3, 2025
Study completion Apr 3, 2025
Sponsor
- Lead sponsor
- EpygenixIndustry
- Sponsor type
- Industry
- Collaborators
- Harmony Biosciences Management, Inc.
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a 3-part, drug-drug interaction study in healthy participants. Each part is designed as a 2-period, fixed-sequence and can be conducted concurrently. Part 1 will assess the effect of itraconazole on the pharmacokinetics (PK) of EPX-100. Part 2 will assess the effect of phenytoin on the PK of EPX-100. Part 3 will assess the effect of EPX-100 on the PK of omeprazole, midazolam, and bupropion.
Conditions
- Drug Drug Interaction
Interventions
EPX-100Drug
Oral solution
ItraconazoleDrug
Oral solution
PhenytoinDrug
Phenytoin sodium extended-release capsules
OmeprazoleDrug
Delayed-release capsule
MidazolamDrug
Midazolam hydrochloride (HCl) syrup
BupropionDrug
Bupropion HCl tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under The Concentration-time Curve (AUC), from Time 0 to the Last Observed Non-zero Concentration (AUC0-t) Of EPX-100Time frame: Up to Day 15
- AUC From Time 0 extrapolated to infinity (AUC0-inf) of EPX-100Time frame: Up to Day 15
- Maximum Observed Concentration (Cmax) of EPX-100Time frame: Up to Day 15
- AUC0-t of OmeprazoleTime frame: Up to Day 15
- AUC0-inf of OmeprazoleTime frame: Up to Day 15
- Cmax of OmeprazoleTime frame: Up to Day 15
- AUC0-t of MidazolamTime frame: Up to Day 15
- AUC0-inf of MidazolamTime frame: Up to Day 15
- Cmax of MidazolamTime frame: Up to Day 15
- AUC0-t of BupropionTime frame: Up to Day 19
- AUC0-inf of BupropionTime frame: Up to Day 19
- Cmax of BupropionTime frame: Up to Day 19
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.